Acorda Therapeutics to Present Update on Phase 3 Study of CVT-301 in Parkinson’s Patients


(May 22, 2017) – Acorda Therapeutics will soon release data on its Phase 3 trial investigating the experimental drug CVT-301 as a potential therapy for patients with Parkinson’s disease. Acorda will present its poster at the International Congress of Parkinson’s Disease and Movement Disorders in Vancouver on June 5th. Read more

Click for a printer friendly version

Back to top